AvenCell Therapeutics

Some of the best links we picked up around the internet

Clinical Update: Dosing Underway in Trial of First...

Mar. 6, 2024

AvenCell Therapeutics recently announced that the first patient has been dosed in a Phase 1A study with its lead product candidate AVC-201. This novel...

CMN Weekly (1 March 2024) - Your Weekly CRISPR...

CMN Weekly

Mar. 1, 2024

Some of the best links we picked up around the internet

European Clinical Trial Approved for First...

Aug. 9, 2023

AvenCell Therapeutics announces that the European Medicines Agency has approved its clinical trial application for AVC-201, a novel CRISPR-edited and...